33P - Idiopathic pulmonary fibrosis as a poor prognostic factor in lung cancer patients

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Cancer in Special Situations
Lung and other Thoracic Tumours
Presenter Choonhee Son
Citation Annals of Oncology (2015) 26 (suppl_1): 6-9. 10.1093/annonc/mdv044
Authors C. Son1, S. Um1, M. Roh2
  • 1Pulmonology, Dong-A University Hospital, 602-715 - Busan/KR
  • 2Pathology, Dong-A University Hospital, 602-715 - Busan/KR



Although idiopathic pulmonary fibrosis (IPF) is known poor prognostic factor of surgically resectable lung cancer, whether IPF also influences prognosis of over all lung cancer is not known. We retrospectively investigate the over all prognosis of lung cancer in IPF.


We reviewed all 1,432 lung cancer (373 small cell carcinoma (SCLC), 524 adenocarcinoma, 462 squamous cell carcinoma, 72 other non-small cell lung cancer(NSCLC)) patients who diagnosed from January 2004 to December 2009. We used the hospital electronic chart to collect data about these patients. In the data base, the following parameters were collected: age, gender, anatomic stage, performance status, survival, treatments, and presence of IPF.


Among 1,432 patients, 124 diagnosed clinically as IPF. Twenty-eight patients (22.6%) were anatomically resectable, but among them 12(9.7%) were inoperable due to poor pulmonary function. After surgical resection, 3(2.4%) suffered acute exacerbation. One patient (0.8%) died of respiratory failure. Although curative dose of radiation (including concurrent chemo-radiation) was indicated in 37 patients (29.8%), only 13 patients (10.5%) completed radiotherapy and 24(19.4%) patients were switched to palliative chemotherapy or supportive care. One patient experienced acute exacerbation after radiotherapy, we cannot differentiate this event with severe radiation pneumonitis and recovered after intensive steroid therapy. During chemotherapy, 3 out of 43 patients experienced acute exacerbation. Among them 2 were received epidermal growth factor receptor tyrosin kinase inhibitors. One patient died of respiratory failure. Five year survival rate of NSCLC without IPF were IA 51%, IB 47%, IIA 27%, IIB 32%, IIIA 11%, IIIB 2%, IV 1%; NSCLC with IPF were IA 38%, IB 41%, IIA 17%, IIB 24%, IIIA 8%, IIIB 2%, IV 0%; SCLC without IPF were limited disease (LD) 9% and extensive disease (ED) 2%; and SCLC with IPF were LD 4% and ED 0%, respectively.


Lung cancer patients with IPF have shorter survival time. Poor pulmonary function and frequent complications during treatment are main causes of poor prognosis in these patients.


All authors have declared no conflicts of interest.